Sepsis – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 8 PAGES: 106

More Info
									                                  Sepsis – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC2000IDB
                                                                                              Publication Date: April 2012




Sepsis – Pipeline Review, H1 2012                                                             GMDHC2000IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Sepsis – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 7
    List of Figures ................................................................................................................................................................................ 8
Introduction......................................................................................................................................................................................... 9
    Global Markets Direct Report Coverage ........................................................................................................................................ 9
Sepsis Overview............................................................................................................................................................................... 10
Therapeutics Development............................................................................................................................................................... 11
    An Overview of Pipeline Products for Sepsis............................................................................................................................... 11
Sepsis Therapeutics under Development by Companies ................................................................................................................. 13
Sepsis Therapeutics under Investigation by Universities/Institutes .................................................................................................. 16
Late Stage Products ......................................................................................................................................................................... 18
    Comparative Analysis .................................................................................................................................................................. 18
Mid Clinical Stage Products.............................................................................................................................................................. 19
    Comparative Analysis .................................................................................................................................................................. 19
Early Clinical Stage Products ........................................................................................................................................................... 20
    Comparative Analysis .................................................................................................................................................................. 20
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 21
    Comparative Analysis .................................................................................................................................................................. 21
Sepsis Therapeutics – Products under Development by Companies ............................................................................................... 22
Sepsis Therapeutics – Products under Investigation by Universities/Institutes ................................................................................ 23
Companies Involved in Sepsis Therapeutics Development .............................................................................................................. 24
    AstraZeneca PLC ........................................................................................................................................................................ 24
    Daiichi Sankyo Company, Ltd...................................................................................................................................................... 25
    Chong Kun Dang Pharmaceutical ............................................................................................................................................... 26
    Eisai Co., Ltd. .............................................................................................................................................................................. 27
    Lorus Therapeutics Inc ................................................................................................................................................................ 28
    Green Cross Corporation ............................................................................................................................................................ 29
    Sirtris Pharmaceuticals, Inc. ........................................................................................................................................................ 30
    Opsona Therapeutics Ltd. ........................................................................................................................................................... 31
    Asahi Kasei Pharma .................................................................................................................................................................... 32
    MSM Protein Technologies, Inc. .................................................................................................................................................. 33
    Viral Genetics, Inc. ...................................................................................................................................................................... 34
    Exponential Biotherapies, Inc. ..................................................................................................................................................... 35
    Atox Bio Inc. ................................................................................................................................................................................ 36
    Cornerstone Therapeutics Inc. .................................................................................................................................................... 37
    Biosynexus Incorporated ............................................................................................................................................................. 38
    NexBio, Inc. ................................................................................................................................................................................. 39
    Aphoenix, Inc. .............................................................................................................................................................................. 40
    ISU ABXIS Co.,Ltd. ..................................................................................................................................................................... 41
Sepsis – Therapeutics Assessment ................................................................................................................................................. 42
    Assessment by Monotherapy Products ....................................................................................................................................... 42
    Assessment by Combination Products ........................................................................................................................................ 43



Sepsis – Pipeline Review, H1 2012                                                                                                                  GMDHC2000IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(2)
Sepsis – Pipeline Review, H1 2012




    Assessment by Route of Administration ...................................................................................................................................... 44
    Assessment by Molecule Type .................................................................................................................................................... 46
Drug Profiles..................................................................................................................................................................................... 49
    E5564 - Drug Profile .................................................................................................................................................................... 49
        Product Description................................................................................................................................................................. 49
        Mechanism of Action ............................................................................................................................................................... 49
        R&D Progress ......................................................................................................................................................................... 49
    CytoFab - Drug Profile ................................................................................................................................................................. 51
        Product Description................................................................................................................................................................. 51
        Mechanism of Action ............................................................................................................................................................... 51
        R&D Progress ......................................................................................................................................................................... 51
    LOR-220 - Drug Profile ................................................................................................................................................................ 52
        Product Description................................................................................................................................................................. 52
        Mechanism of Action ............................................................................................................................................................... 52
        R&D Progress ......................................................................................................................................................................... 52
    ART-123 - Drug Profile ................................................................................................................................................................ 53
        Product Description................................................................................................................................................................. 53
        Mechanism of Action ............................................................................................................................................................... 53
        R&D Progress ......................................................................................................................................................................... 53
    EA-230 - Drug Profile .................................................................................................................................................................. 55
        Product Description................................................................................................................................................................. 55
        Mechanism of Action ............................................................................................................................................................... 55
        R&D Progress ......................................................................................................................................................................... 55
    Pagibaximab - Drug Profile .......................................................................................................................................................... 57
        Product Description................................................................................................................................................................. 57
        Mechanism of Action ............................................................................................................................................................... 57
        R&D Progress ......................................................................................................................................................................... 57
    AFX-300 series - Drug Profile ...................................................................................................................................................... 59
        Product Description................................................................................................................................................................. 59
        Mechanism of Action ............................................................................................................................................................... 59
        R&D Progress ......................................................................................................................................................................... 59
    HMGB1 Program - Drug Profile ................................................................................................................................................... 60
        Product Description................................................................................................................................................................. 60
        Mechanism of Action ............................................................................................................................................................... 60
        R&D Progress ......................................................................................................................................................................... 60
    CKD-712 - Drug Profile ................................................................................................................................................................ 61
        Product Description................................................................................................................................................................. 61
        Mechanism of Action ............................................................................................................................................................... 61
        R&D Progress ......................................................................................................................................................................... 61
    Viradin - Drug Profile ................................................................................................................................................................... 62
        Product Description................................................................................................................................................................. 62
        Mechanism of Action ............................................................................................................................................................... 62
        R&D Progress ......................................................................................................................................................................... 62
    Cefazolin - Drug Profile ............................................................................................................................................................... 63


Sepsis – Pipeline Review, H1 2012                                                                                                                GMDHC2000IDB / Pub April 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(3)
Sepsis – Pipeline Review, H1 2012




        Product Description................................................................................................................................................................. 63
        Mechanism of Action ............................................................................................................................................................... 63
        R&D Progress ......................................................................................................................................................................... 63
    Hydrocortisone - Drug Profile ...................................................................................................................................................... 64
        Product Description................................................................................................................................................................. 64
        Mechanism of Action ............................................................................................................................................................... 64
        R&D Progress ......................................................................................................................................................................... 64
    Piperacillin + Tazobactam - Drug Profile ..................................................................................................................................... 66
        Product Description................................................................................................................................................................. 66
        Mechanism of Action ............................................................................................................................................................... 66
        R&D Progress ......................................................................................................................................................................... 66
    Cotrimoxazole - Drug Profile........................................................................................................................................................ 67
        Product Description................................................................................................................................................................. 67
        Mechanism of Action ............................................................................................................................................................... 67
        R&D Progress ......................................................................................................................................................................... 67
    Simvastatin - Drug Profile ............................................................................................................................................................ 68
        Product Description................................................................................................................................................................. 68
        Mechanism of Action ............................................................................................................................................................... 68
        R&D Progress ......................................................................................................................................................................... 68
    AB103 - Drug Profile.................................................................................................................................................................... 69
        Product Description................................................................................................................................................................. 69
        Mechanism of Action ............................................................................................................................................................... 69
        R&D Progress ......................................................................................................................................................................... 69
    Procaine Penicillin + Gentamicin + Amoxicillin - Drug Profile ...................................................................................................... 70
        Product Description................................................................................................................................................................. 70
        Mechanism of Action .............................................................................................................................................................
								
To top